Cancer drugs could halt Ebola virus

Some cancer drugs used to treat patients with leukemia may also help stop the Ebola virus and give the body time to control the infection before it turns deadly, US researchers said on Wednesday.

The much-feared emerged in Africa in the 1970s and can incite a hemorrhagic fever which causes a person to bleed to death in up to 90 percent of cases.

While rare, the Ebola virus is considered a potential weapon for bioterrorists because it is so highly contagious, so lethal and has no standard treatment.

But a pair of well-known drugs that have been used to treat leukemia -- known as nolitinib and imatinib -- appear to have some success in stopping the virus from replicating in human cells.

Lead researcher Mayra Garcia of the US National Institute of Allergy and Infectious Diseases and colleagues reported their finding in Wednesday's edition of the journal Science Translational Medicine.

By experimenting with human embryonic in a lab, they found that a protein called c-Abl1 was a key regulator in whether the Ebola virus could replicate or not.

The leukemia drugs work by stopping that protein's activity. In turn, a viral protein called VP40 stopped the release of from the infected cells, a process known as filovirus budding.

"Drugs that target filovirus budding would be expected to reduce the spread of infection, giving the immune system time to control the infection," the study authors wrote.

"Our results suggest that short-term administration of nilotinib or imatinib may be useful in treating Ebola virus infections."

Imatinib, which is marketed as Gleevec and Glivec, is used to treat in humans, a disease which is caused by dysregulation of c-Abl enzyme.

Nilotinib, also known as Tasigna, has been used in chronic myelogenous leukemia patients who are resistant to imatinib.

Both "have reasonable safety profiles, although some has been reported with long-term administration in a small number of patients," the study added.

According to the UN's World Health Organization (WHO), about 1,850 cases of Ebola, with some 1,200 deaths, have occurred since 1976.

The virus has a natural reservoir in several species of African fruit bat. Gorillas and other non-human primates are also susceptible to the disease.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

13 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

14 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments